DelSiTech enters into research collaboration with Orion Corporation
(Thomson Reuters ONE) - DelSiTech Ltd, Turku, Finland, has signed a collaboration agreementwith Orion Corporation. The agreement enables Orion to apply theunique and proprietary DelSiTech® drug delivery technology incombination with its drug molecules for different therapeuticpurposes. DelSiTech will receive fully allocated payments forproject work and also milestone payments tied to the progress ofpossible development projects. The agreement contains also an optionfor licensing and further collaboration.Dr. Harry Jalonen, CEO of DelSiTech said: "We are proud to have beenchosen by Orion as a partner for the development of new innovativedrug delivery products. We have great expectations regarding thecooperation with the highly skilled personnel of Orion. Thisagreement opens possibilities for the DelSiTech drug deliverytechnology in new interesting fields. An important advantage is alsothat Orion's R&D centre in Turku is located close to the site ofDelSiTech.Dr. Antti Haapalinna, Vice President, Research of Orion said: "We arehappy to partner with DelSiTech and start research collaboration onthe possible applications of this interesting delivery technology. InOrion, this kind of activity represents strategic researchpartnership, in which the parties join their knowledge to develop newmedicines with added therapeutic value.DelSiTech technologyThe DelSiTech® drug delivery technology is a result of across-disciplinary project including top researchers from theUniversity of Turku and ÿbo Akademi, the Swedish-speaking Universityin Turku.The Biomaterial Research Group includes dentists,physicians, chemists, engineers and pharmacists and is globally oneof the largest of its kind in the research of bioactive glass,sol-gel and glass fiber reinforced materials mainly for dental,orthopedic and drug delivery applications.After the transfer of the technology, DelSiTech has started theindustrialization process of the same. By combining the in depthknow-how and intellectual property of silica chemistry with thenewest nano technology it has been possible to encapsulate andcontrollably release extremely labile viruses and proteins toclinically useful applications. As the result of this work DelSiTechis today the leading company in the world in the field of controlleddelivery of viruses. This application is expected to become soon ahighly interesting and important field e.g. in the treatment ofcancer.It has been reported in several major international scientificcongresses and publications that this technology works well inanimals with small molecular drugs and live virus. The technology isprotected by 9 international patent families covering about 100patents and patent applications. DelSiTech has today several projectsunder development with companies in Europe, the USA and Asia. One ofthese projects is the licensing agreement with the global pharmacompany Bayer in the field of wound treatment.DelSiTech LtdDelSiTech is a drug delivery company headquartered in Turku, Finland.DelSiTech Ltd started operations in late 2003. DelSiTech Ltdspecializes in a unique and proprietary silica-based drug deliverytechnology DelSiTech® for controlled release with applications insmall molecular drugs and biopharmaceuticals: proteins,polysaccharides (heparin) and viruses. The main use is for implants,subcutaneous and intra-muscular administration mainly for cancer,neurological and orthopedic applications.For more about DelSiTech, please visit www.delsitech.comOrionOrion Corporation is a Finnish listed company, which develops,manufactures and markets pharmaceuticals, active pharmaceuticalingredients and diagnostic tests for global markets. Orion has beenbuilding well-being for over 90 years. Pharmaceuticals account forabout 95% of Orion's net sales, of which a considerable part comesfrom proprietary patented pharmaceutical innovations. Orion carrieson intensive research with the aim of introducing new innovativetreatments to global markets. The core therapy areas in Orion'sproduct and research strategy are central nervous system, oncologyand critical care, and respiratory medicines administered with theEasyhaler device.In global marketing, Orion collaborates in partnerships with otherpharmaceutical companies. Stalevo® and Comtess®/Comtan®, forParkinson's Disease, are the largest products by sales in Orion'sportfolio. These products are marketed in collaboration withNovartis, and they are the most significant globally marketedproducts for Orion.Orion also has a large portfolio of generic, off-patent prescriptionmedicines, hospital treatments and self-care products. These productsare sold mainly in Finland, other Nordic countries, the new EUcountries and Germany.For more about Orion, please visit www.orion.fi/englishContact person for this press release:Harry Jalonen, CEO, DelSiTech Ltd+358 2 4788 640 or +358 50 336 7972harry.jalonen(at)delsitech.comThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 07.10.2009 - 12:00 Uhr
Sprache: Deutsch
News-ID 6674
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DelSiTech enters into research collaboration with Orion Corporation"
steht unter der journalistisch-redaktionellen Verantwortung von
DelSiTech Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
